Work

Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM)

Year: 2011

Type: article

Source: Blood

DOI: 10.1182/blood.v118.21.2933.2933

Authors: Jesús F San Miguel, Paul G. Richardson, Robert Z. Orlowski, Hartmut Goldschmidt, Deyanira Corzo, Carol Satler, Dixie-Lee Esseltine, Rachel Neuwirth, Maria Ponsillo, Andrew Z Cakana, Jay King, William M Deraedt, Avinash Desai, Yana Lutska, Dina Gifkins, Kevin Liu, Pieter Sonneveld

Institutions: Complejo Hospitalario de Salamanca, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Heidelberg University, National Center for Tumor Diseases, Takeda Oncology (United States), Janssen (United Kingdom), Janssen Research & Development (United States), Janssen (Belgium), Erasmus MC

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2490786107

FWCI: 1.301

Cites:

Cited by: 9

Related to: 10